Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors Journal Article
| Authors: | Raymond, E.; Hobday, T.; Castellano, D.; Reidy-Lagunes, D.; García-Carbonero, R.; Carrato, A. |
| Article Title: | Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors |
| Abstract: | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs. © 2011 Springer Science+Business Media, LLC. |
| Keywords: | cancer chemotherapy; cancer survival; protein expression; treatment response; overall survival; fatigue; neutropenia; sorafenib; bevacizumab; cisplatin; doxorubicin; fluorouracil; raf protein; sunitinib; advanced cancer; diarrhea; drug efficacy; hypertension; liver cell carcinoma; monotherapy; nonhuman; solid tumor; unspecified side effect; capecitabine; gemcitabine; paclitaxel; pancreas cancer; endometrium cancer; colorectal cancer; carboplatin; peginterferon alpha2b; unindexed drug; progression free survival; drug eruption; multiple cycle treatment; multiple myeloma; ovary cancer; breast cancer; etoposide; leukopenia; lung non small cell cancer; nausea; myalgia; dasatinib; angiogenesis; kidney carcinoma; carcinogenesis; cixutumumab; docetaxel; protein tyrosine kinase inhibitor; temsirolimus; abdominal pain; asthenia; drug receptor binding; hyperglycemia; neuroendocrine tumor; chemotherapy induced emesis; drug fatality; drug induced headache; folinic acid; pancreas tumor; liver cancer; carcinoid; targeted therapy; octreotide; alpha2a interferon; kidney cancer; oxaliplatin; hand foot syndrome; pemetrexed; everolimus; 2 methoxyestradiol; pertuzumab; nvp aew 541; fluindostatin; carcinoid tumors; igf-1r; orphan disease; pancreatic neuroendocrine tumors; zollinger ellison syndrome; dalotuzumab; pancreatic neuroendocrine tumor; gastroenteropancreatic neuroendocrine tumor |
| Journal Title: | Cancer and Metastasis Reviews |
| Volume: | 30 |
| Issue: | Suppl. 1 |
| ISSN: | 0167-7659 |
| Publisher: | Springer |
| Date Published: | 2011-03-01 |
| Start Page: | S19 |
| End Page: | S26 |
| Language: | English |
| DOI: | 10.1007/s10555-011-9291-2 |
| PROVIDER: | scopus |
| PUBMED: | 21308478 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 23 June 2011" - "CODEN: CMRED" - "Source: Scopus" |
